Furthermore, although the transforming growth factor-β (TGF-β)/SMAD signaling pathway is recognized as a key driver of atrial fibrosis (Saljic et al. 2022; Lai et al. 2022), the upstream regulators of this pathway under CKD conditions remain poorly defined. This evidence concerns the gene TGFB1 and chronic kidney disease.